India Names Panel To Guard Latest Multi-Resistant TB Drug From Overuse
This article was originally published in PharmAsia News
Executive Summary
India's health ministry has formed a panel of experts to find ways to be sure a new tuberculosis drug, bedaquilline, is not overly used, contributing to development of drug-resistant varieties of the disease.